
|Articles|October 24, 2012
VMA treatment approved
The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
From then to next: Five decades of transformation in ophthalmology
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease
5


















































.png)


